Important News & Announcements

Stay up to date with the latest news and announcements from NASCSA.

Back to all news

FDA Alerts Health Care Professionals of Risks to Patients Exposed to Xylazine in Illicit Drugs

Posted 11/17/2022

Fentanyl, as well as other illicit drugs, can be contaminated with xylazine, warns FDA. Xylazine, an FDA-approved sedative and pain reliever for animals, is not safe for humans and can result in life-threatening side effects, similar to those commonly associated with opioid use. Naloxone can reverse the effects of opioid overdoses. However, as of right now, it is not known if naloxone can reverse the effects of xylazine exposure. Health care professionals are advised to continue to administer naloxone for opioid overdoses and monitor for possible xylazine exposure if patients do not respond to naloxone or exhibit signs and symptoms of xylazine exposure, such as severe necrotic skin ulcerations. Health care professionals should provide appropriate supportive measures to patients who do not respond to naloxone.  Read the full press release here.

Back to all news

Sponsor Spotlight


Bamboo Health
Prescription Drug Monitoring Programs (PDMPs) are critical to the mission of the National Association of State Controlled Substances Authorities (NASCSA), helping to prevent the misuse and diversion of controlled substances. Bamboo Health provides the nation’s most comprehensive prescription drug monitoring program (PDMP) solutions through our years of experience with partnerships across 44 unique PDMPs. Bamboo Health's advanced analytics, real-time clinical decision support, and critical insights and interventions support more than 1.6 million physicians, pharmacists, and care team members across hundreds of millions of patients encounters each year.

Our solutions have demonstrated leadership and continued support of state PDMP innovations designed to maximize the effectiveness of the PDMP for its users. Our solutions include the ability to add clinical tools such as clinical alerts, intuitive data graphs, peer-to-peer messaging which enable prescribers and pharmacists to better evaluate PDMP reports. In addition, Bamboo Health’s PDMP integration protocol through the PMP Gateway solution supports an estimated 1 billion patient queries annually across 48 states. States who adopt our statewide integration solution realize a 6-8-fold increase in PDMP queries while significantly improving user satisfaction. As responsible leaders in this market, we are proud to partner with our State PDMP partners to continue to innovate and enhance our solutions to deliver on this mission, ensuring that we get the right information in front of the right clinicians, at the right time, and in the right place. For more information visit www.Bamboohealth.com

All Sponsors